Please login to the form below

Not currently logged in
Email:
Password:

metformin

This page shows the latest metformin news and features for those working in and with pharma, biotech and healthcare.

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

first nine months of the year, helped by data suggesting it is superior to Trulicity in maintaining glucose control when added to background treatment with metformin.

Latest news

More from news
Approximately 6 fully matching, plus 151 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Complements are products that are often used together. Sometimes this distinction becomes blurred, as with metformin, which is a treatment for type II diabetes in its own right and also used ... market. The large product beside Januvia is metformin that,

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage. ... We probably have the broadest offering of products in diabetes in that middle space from when people start in

  • Pharma deals during November 2013 Pharma deals during November 2013

    The all-cash transaction is expected to close in Q1 2014. The combined company will market 22 products, including Xifaxan (rifaximin; 2012 sales of $514.5m) and Santarus' therapy Glumetza (metformin)

  • Rise of generic medicines in Portugal Rise of generic medicines in Portugal

    Generics bestsellers in volume. Simvastatin. Alprazolam. Oneprazol. Ibuprofen. Paracetamol. Metformin. Nimesulide.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    The most commonly used oral/ non-insulin injectables are Metformin (37 per cent), Glucobay (21 per cent), Glipizide (15 per cent) and Tangshiping (11 per cent). ... In March 2013, Merck Serono and Bristol-Myers Squibb struck a deal to co-promote a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics